SVRA Stock Summary and Trading Ideas (Savara | NASDAQ:SVRA)

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara trades on the NASDAQ stock market under the symbol SVRA.

As of July 17, 2026, SVRA stock price was flat at $5.52 with 955,855 million shares trading.

SVRA has a beta of 1.52, meaning it tends to be more sensitive to market movements. SVRA has a correlation of 0.11 to the broad based SPY ETF.

SVRA has a market cap of $1.13 billion. This is considered a Small Cap stock.

In the last 3 years, SVRA traded as high as $7.01 and as low as $1.89.

The top ETF exchange traded funds that SVRA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

SVRA has outperformed the market in the last year with a return of +135.9%, while the SPY ETF gained +19.5%. However, in the most recent history, SVRA shares have underperformed the stock market with its stock returning -4.5% in the last 3 month period and -11.3% for the last 2 week period, while SPY has returned +4.9% and -0.2%, respectively.

SVRA support price is $5.35 and resistance is $5.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SVRA shares will trade within this expected range on the day.